NasdaqGM:IRMDMedical Equipment
How Record Q3 Results And FDA-Cleared MRI Pump Launch At IRADIMED (IRMD) Has Changed Its Investment Story
Riverwater Partners recently highlighted IRADIMED CORPORATION as the top contributor to its Micro Opportunities Strategy in 2025, following record Q3 2025 revenue of US$21.2 million and FDA approval of the company’s MRI-compatible 3870 IV infusion pump in July 2025.
Beyond the financial headlines, IRADIMED’s combination of accelerating revenue, new FDA-cleared technology and a special dividend, alongside insider share sales and a “Moderate Buy” analyst consensus, paints a complex picture of...